You are here
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
JERUSALEM, Israel, May 13, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel.
Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.
Details of Dr. Ben-Yedidia's presentation:
Update of the Pivotal, Clinical Efficacy, Phase 3 trial of BiondVax's M-001 Universal Influenza Vaccine
Date: Wednesday, May 15, 2019
Time: 16:40 - 16:55
Location: Hall B, David InterContinental Hotel, Tel Aviv, Israel
BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. Please visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new manufacturing facility; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. We undertake no obligation to revise or update any forward-looking statement for any reason.
Joshua E. Phillipson
View original content to download multimedia:http://www.prnewswire.com/news-releases/biondvax-to-provide-update-of-m-001-universal-flu-vaccine-pivotal-phase-3-clinical-trial-at-18th-mixiii-biomed-conference-300848716.html
SOURCE BiondVax Pharmaceuticals Ltd.